Trial Profile

Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HSP Gp96 vaccine Cure and Sure Biotech (Primary)
Indications Adenocarcinoma; Liver cancer; Pancreatic cancer
Focus Adverse reactions
Sponsors Cure&Sure Biotech

Most Recent Events

10 Dec 2015 Planned End Date changed from 1 Jul 2016 to 1 Nov 2019 as reported by ClinicalTrials.gov record.
10 Dec 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
10 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com